Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia

被引:10
|
作者
Gajzer, David C. [1 ,2 ]
Tjendra, Youley [1 ]
Kerr, Darcy A. [3 ,4 ]
Algashaamy, Khaled [1 ]
Zuo, Yiqin [1 ]
Menendez, Silvia Gra [5 ]
Jorda, Merce [1 ]
Garcia-Buitrago, Monica [1 ]
Gomez-Fernandez, Carmen [1 ]
Torres, Jaylou M. Velez [1 ]
机构
[1] Univ Miami, Dept Pathol & Lab Med, Miller Sch Med, 1400 NW 12th Ave, Miami, FL 33136 USA
[2] Univ Washington, Dept Lab Med & Pathol, Sch Med, Seattle, WA USA
[3] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lebanon, NH USA
[4] Geisel Sch Med, Lebanon, NH USA
[5] Univ Miami, Dept Med, Miller Sch Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA
关键词
atypia of undetermined significance (AUS); BRAFV600E; molecular testing; molecular-derived risk of malignancy (MDROM); probability of malignancy (POM); RAS; ThyroSeq version 3 genomic classifier (ThyroSeq v3 GC); ENCAPSULATED FOLLICULAR VARIANT; HYALINIZING TRABECULAR ADENOMA; GENE-EXPRESSION CLASSIFIER; UNDETERMINED SIGNIFICANCE; BETHESDA SYSTEM; CYTOLOGIC FEATURES; MUTATIONS; NODULES; TUMORS; REARRANGEMENTS;
D O I
10.1002/cncy.22617
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background ThyroSeq assesses the probability of malignancy (POM) in thyroid fine-needle aspiration cytology specimens diagnosed as atypia of undetermined significance (AUS). The authors investigated whether defined AUS subcategories are associated with specific molecular alterations, the molecular-derived risk of malignancy (MDROM), and the risk of malignancy (ROM). Methods Fine-needle aspiration cytology reports of AUS and corresponding results from the ThyroSeq version 3 genomic classifier results were retrieved and subcategorized as follicular cells with either cytologic atypia (FC-C), architectural atypia (FC-A), both cytologic and architectural atypia (FC-CA), or a predominance of Hurthle cells (PHC). The MDROM, ROM, and frequency of molecular alterations by subcategory were computed and analyzed, and p < .05 was considered significant. Results The final analysis included 541 cases subdivided into 233 with FC-A, 104 with FC-C, 116 with FC-CA, and 88 with PHC. The benign call rate and positive call rate for the AUS category were 72% and 28%, respectively, which varied between AUS subcategories. The MDROM by subcategory was 15.9% FC-A, 20.5% FC-C, 33.8% FC-CA, and 14.4% PHC. Histologic follow-up was available for 155 (28%) AUS cases with a follow-up period >= 12 months. The 95% confidence intervals of the MDROMs overlapped with the ROMs. The highest MDROM and ROM were in the FC-CA subcategory. RAS mutations were present in all subcategories. BRAF V600E mutations and papillary thyroid carcinoma were most frequent in the FC-CA subcategory. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features was significantly more frequent in the FC-C subcategory. Conclusions The current results demonstrated that AUS subcategories are associated with specific genetic alterations, the MDROM, and the ROM. Molecular results and an awareness of various cancer probabilities within AUS subcategories can allow for a more tailored management.
引用
收藏
页码:881 / 890
页数:10
相关论文
共 5 条
  • [1] Probability of malignancy and molecular alterations as determined by ThyroSeq v3 genomic classifier in Bethesda Category IV
    Tjendra, Youley
    Kerr, Darcy A.
    Zuo, Yiqin
    Menendez, Silvia Gra
    Jorda, Merce
    Gomez-Fernandez, Carmen
    Torres, Jaylou M. Velez M.
    CANCER CYTOPATHOLOGY, 2023, 131 (09) : 586 - 595
  • [2] Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology
    Nikiforov, Yuri E.
    Baloch, Zubair W.
    CANCER CYTOPATHOLOGY, 2019, 127 (04) : 225 - 230
  • [3] Surgical Outcomes of Thyroid Nodules Positive for Gene Expression Alterations Using ThyroSeq V3 Genomic Classifier
    Salameh, Samer
    Rajab, Mohannad
    Forest, Veronique-Isabelle
    Pusztaszeri, Marc
    Payne, Richard J. J.
    CANCERS, 2023, 15 (01)
  • [4] Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology
    Torres, Jaylou M. Velez
    Curnow, Porshya M.
    Tjendra, Youley
    Jorda, Merce
    Fernandez, Carmen Gomez
    Buitrago, Monica Garcia
    Zuo, Yiqin
    Cordero, Roberto Ruiz
    CANCER CYTOPATHOLOGY, 2024, 132 (08) : 491 - 498
  • [5] High-risk and intermediate-high-risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution
    Jug, Rachel
    Foo, Wen-Chi
    Jones, Claudia
    Ahmadi, Sara
    Jiang, Xiaoyin Sara
    CANCER CYTOPATHOLOGY, 2020, 128 (08) : 563 - 569